Adenovirus‐mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma

Andrawiss, Mariam; Maron, A; Beltran, William A.; Opolon, Paule; Connault, Elisabeth; Griscelli, Frank; Yeh, Patrice; Perricaudet, Michel; Devauchelle, Patrick

doi:10.1002/1521-2254(200105/06)3:3<228::aid-jgm186>3.3.co;2-1

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To demonstrate the potential of such an approach, antisense oligonucleotide silencing of miR‐182 prevented metastatic progression in a mouse model of melanoma liver metastasis . Targeting of canine UM metastasis by inhibition of 1 or more metastasis‐inducing miRNAs is plausible, given that transduction of canine UM by direct intratumoural injection of a recombinant adenovirus has already been demonstrated …”

Section: Discussionmentioning

confidence: 99%

Metastasis‐associated microRNA expression in canine uveal melanoma

Starkey

Compston‐Garnett

Malho

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Metastasis‐associated microRNA expression in canine uveal melanoma

Starkey

Compston‐Garnett

Malho

et al. 2017

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…In the dog a single report has described its use to transduce the ciliary body and iris as an approach to target uveal melanomas. Successful delivery to the anterior uvea and into a canine iridal tumor was achieved; however, induction of a severe cellular and humoral immune response was observed in all treated animals 56 . Lentivirus vectors can package a genome up to 10 kb but their cell tropism is limited to the RPE.…”

Section: Canine Models Of Rd Used For Therapeutic Assessmentmentioning

confidence: 99%

The use of canine models of inherited retinal degeneration to test novel therapeutic approaches

Beltran¹

2009

Veterinary Ophthalmology

View full text Add to dashboard Cite

Inherited retinal degenerations (RDs) are a common cause of blindness in dogs and in humans. Over the past two decades numerous genes causally associated with these diseases have been identified and several canine models have been used to improve our understanding of the molecular mechanisms of RDs, as well as to test the proof of principle and safety of novel therapies. This review briefly summarizes the drug delivery approaches and therapeutic strategies that have been and are currently tested in dogs, with a particular emphasis on corrective gene therapy, and retinal neuroprotection.

show abstract

“…Gene therapy has also been explored as a potential therapy for red-green colour blindness,73 corneal neovascularisation,74 a variety of other corneal diseases, including allograft rejection, postexcimer laser scarring and herpes simplex keratitis,93 uveal melanoma94 and optic nerve diseases, including optic nerve trauma, optic neuritis and Leber's hereditary optic neuropathy 95…”

Section: Ocular Gene Therapy In Experimental Modelsmentioning

confidence: 99%

Gene therapy for ocular diseases

Liu

Tuo

Chan

2010

British Journal of Ophthalmology

View full text Add to dashboard Cite

The eye is an easily accessible, highly compartmentalised and immune-privileged organ that offers unique advantages as a gene therapy target. Significant advancements have been made in understanding the genetic pathogenesis of ocular diseases, and gene replacement and gene silencing have been implicated as potentially efficacious therapies. Recent improvements have been made in the safety and specificity of vector-based ocular gene transfer methods. Proof-of-concept for vector-based gene therapies has also been established in several experimental models of human ocular diseases. After nearly two decades of ocular gene therapy research, preliminary successes are now being reported in phase 1 clinical trials for the treatment of Leber congenital amaurosis. This review describes current developments and future prospects for ocular gene therapy. Novel methods are being developed to enhance the performance and regulation of recombinant adeno-associated virus- and lentivirus-mediated ocular gene transfer. Gene therapy prospects have advanced for a variety of retinal disorders, including retinitis pigmentosa, retinoschisis, Stargardt disease and age-related macular degeneration. Advances have also been made using experimental models for non-retinal diseases, such as uveitis and glaucoma. These methodological advancements are critical for the implementation of additional gene-based therapies for human ocular diseases in the near future.

show abstract

Adenovirus‐mediated gene transfer in canine eyes: a preclinical study for gene therapy of human uveal melanoma

Abstract: The present study involving adenovirus-mediated gene transfer to dog eyes provides an essential basis for gene therapy treatment of uveal melanoma-bearing patients.

Cited by 8 publications

References 0 publications

Metastasis‐associated microRNA expression in canine uveal melanoma

Metastasis‐associated microRNA expression in canine uveal melanoma

The use of canine models of inherited retinal degeneration to test novel therapeutic approaches

Gene therapy for ocular diseases

Contact Info

Product

Resources

About